Elranatamab
- Generic Name
- Elranatamab
- Brand Names
- Elrexfio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2408850-14-4
- Unique Ingredient Identifier
- L0HR9A577V
- Background
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each of which contributes one heavy chain and one light chain to drug structure. The resulting 4-chain bispecific antibody is c...
- Indication
Elranatamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Elranatamab in R/R Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06138275
- Locations
- 🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT06057402
- Locations
- 🇫🇷
Hôpital Saint-Louis, Paris, France
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, Rhône, France
Self-administration of Subcutaneous Elranatamab in the Patients' Homes.
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Thomas Lund
- Target Recruit Count
- 20
- Registration Number
- NCT06015542
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 514
- Registration Number
- NCT05932290
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05927571
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center PPDS, Tel Aviv-Yafo, Israel
🇮🇱Sheba Medical Center - PPDS, Ramat Gan, Israel
🇦🇺The Alfred Hospital, Prahan, Victoria, Australia
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05675449
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida, United States
🇺🇸Johns Hopkins Medicine, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1116
- Registration Number
- NCT05623020
- Locations
- 🇮🇹
ASL PESCARA-Presidio Ospedaliero Pescara, Pescara, Italy
🇮🇹AOU Policlinico Umberto I, Roma, Italy
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 508
- Registration Number
- NCT05565391
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 760
- Registration Number
- NCT05317416
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Madrid, Comunidad DE, Spain
🇺🇸Banner Gateway Medical Center, Gilbert, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
- Conditions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05238311
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.